Lab testing giant, approaching $500M in revenue, welcomes new CEO

Fort Myers cancer-focused genetic testing services and oncology contract research firm NeoGenomics released its second-quarter earnings report last week, including some statements about the firm’s new CEO, Chris Smith.

Smith was named CEO on July 21, effective Monday, Aug. 15. He replaces interim CEO Lynn Tetrault, who will resume her role as independent board chair while assisting in the transition of responsibilities, according to a statement. Tetrault had been interim CEO since March, when Mark Mallon, who had been CEO for a little over a year, resigned in the wake of an underperforming earnings report.